Efficacy, Safety, and Economic Evaluation of Originator Versus Generic Moxifloxacin Hydrochloride Injection in the Treatment of Community-Acquired Pneumonia Under China's National Centralized Drug Procurement Policy: A Retrospective Study
Efficacy, Safety, and Economic Evaluation of Originator Versus Generic Moxifloxacin Hydrochloride Injection in the Treatment of Community-Acquired Pneumonia Under China's National Centralized Drug Procurement Policy: A Retrospective Study. // Clinical Therapeutics. – URL: https://www.sciencedirect.com/science/article/pii/S0149291826003346?dgcid=rss_sd_all
Efficacy, Safety, and Economic Evaluation of Originator Versus Generic Moxifloxacin Hydrochloride Injection in the Treatment of Community-Acquired Pneumonia Under China's National Centralized Drug Procurement Policy: A Retrospective Study. Clinical Therapeutics. https://www.sciencedirect.com/science/article/pii/S0149291826003346?dgcid=rss_sd_all
“Efficacy, Safety, and Economic Evaluation of Originator Versus Generic Moxifloxacin Hydrochloride Injection in the Treatment of Community-Acquired Pneumonia Under China's National Centralized Drug Procurement Policy: A Retrospective Study.” Clinical Therapeutics.
@article{article93566,
title = {Efficacy, Safety, and Economic Evaluation of Originator Versus Generic Moxifloxacin Hydrochloride Injection in the Treatment of Community-Acquired Pneumonia Under China's National Centralized Drug Procurement Policy: A Retrospective Study},
journal = {Clinical Therapeutics},
url = {https://www.sciencedirect.com/science/article/pii/S0149291826003346?dgcid=rss_sd_all}
}